Article Text

This article has a correction. Please see:

other Versions

PDF
Mesenchymal stem cells in rheumatoid synovium: Enumeration and functional assessment in relation to synovial inflammation level
  1. E Jones (msjej{at}leeds.ac.uk)
  1. Academic Unit of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, United Kingdom
    1. S M Churchman (s.m.churchman{at}leeds.ac.uk)
    1. Academic Unit of Musculoskeletal, United Kingdom
      1. A English (a.a.english{at}leeds.ac.uk)
      1. Academic Unit of Musculoskeletal, United Kingdom
        1. M H Buch (m.buch{at}leeds.ac.uk)
        1. Academic Unit of Musculoskeletal, United Kingdom
          1. E A Horner (e.a.horner{at}leeds.ac.uk)
          1. Academic Unit of Musculoskeletal, United Kingdom
            1. C H Burgoyne (c.h.burgoyne{at}leeds.ac.uk)
            1. Academic Unit of Musculoskeletal, United Kingdom
              1. R Reece (richard.reece{at}cht.nhs.uk)
              1. Huddersfield Royal Infirmary, United Kingdom
                1. S Kinsey (sally.kinsey{at}leedsth.nhs.uk)
                1. Paediatric Haematology, University of Leeds, United Kingdom
                  1. P Emery (p.emery{at}leeds.ac.uk)
                  1. Academic Unit of Musculoskeletal, United Kingdom
                    1. D McGonagle (d.g.mcgonagle{at}leeds.ac.uk)
                    1. Academic Unit of Musculoskeletal, United Kingdom
                      1. F Ponchel (f.ponchel{at}leeds.ac.uk)
                      1. Academic Unit of Musculoskeletal, United Kingdom

                        Abstract

                        Objective: Achieving joint regeneration in rheumatoid arthritis (RA) represents a future challenge. Autologous synovial mesenchymal stem cells (MSCs) could be therapeutically exploited. However, the inflammatory milieu in the RA synovium could adversely affect endogenous MSC function. To test this hypothesis, the frequency and multipotency of RA synovial MSCs was evaluated in relation to existing synovial inflammation.

                        Methods: Synovial inflammation was measured using arthroscopic visual analogue score (VAS) and further validated using immunohistochemistry and flow cytometry. Highly-proliferative clonogenic in vivo MSCs were enumerated following fluorescence-activated cell sorting and expansion for 20 population doublings. MSC multipotency was quantified following standard in vitro culture-expansion and trilineage differentiation assays. Real-time PCR, flow cytometry and ELISA were used to evaluate pro- and anti-chondrogenic molecules in standard polyclonal synovial MSCs.

                        Results: Arthroscopic visual score of inflammation (VAS) significantly correlated with synovial macrophage infiltration. In RA, synovial MSC chondrogenesis was inhibited in direct relation to VAS (r=-0.777, p<0.05) and reduced compared to control OA-MSCs (p<0.05). In vivo MSCs resided in the synovial fibroblastic/stromal fraction (CD45-CD31-) and were reduced in frequency in relation to VAS (r=-0.695, p<0.05). In RA-MSCs, CD44 levels correlated negatively with inflammation and positively with chondrogenesis (r=-0.830 and r=0.865, respectively). Cytokine production and Sox9 expression was similar between RA- and OA-MSCs.

                        Conclusions: Our findings demonstrate a negative relationship between synovial MSC chondrogenic and clonogenic capacities and the magnitude of synovitis in RA. Effective suppression of joint inflammation is therefore necessary for the development of autologous MSC therapies aimed at cartilage regeneration in RA.

                        Statistics from Altmetric.com

                        Request permissions

                        If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

                        Linked Articles

                        • Miscellaneous
                          BMJ Publishing Group Ltd and European League Against Rheumatism